Safety and Efficacy of Ilaprazole 5, 20 and 40 mg QD and Lansoprazole 30 mg QD on Healing of Erosive Esophagitis

PHASE2CompletedINTERVENTIONAL
Enrollment

831

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

October 31, 2007

Study Completion Date

October 31, 2007

Conditions
Esophagitis
Interventions
DRUG

Ilaprazole

Ilaprazole 5 mg, capsules, orally, once daily for up to 8 weeks.

DRUG

Ilaprazole

Ilaprazole 20 mg, capsules, orally, once daily for up to 8 weeks.

DRUG

Ilaprazole

Ilaprazole 40 mg, capsules, orally, once daily for up to 8 weeks.

DRUG

Lansoprazole

Lansoprazole 30 mg, capsules, orally, once daily for up to 8 weeks.

Trial Locations (94)

Unknown

Hueytown

Huntsville

Chandler

Phoenix

Tempe

Tucson

Sherwood

Anaheim

Cypress

Encinitas

Garden Grove

Irvine

Lancaster

Mission Hills

Oakland

Orange

Pasadena

San Diego

West Covina

Colorado Springs

Longmont

Pueblo

Bristol

Washington D.C.

Longwood

Miami

New Smyrna Beach

Pembroke Pines

Tampa

Zephyrhills

Atlanta

Conyers

Newnan

Tucker

Boise

Moline

Rockford

Clive

Davenport

Dubuque

Wichita

Metairie

Chevy Chase

Prince Frederick

Olive Branch

Jefferson City

Kansas City

Mexico

Egg Harbor

Albuquerque

Binghamton

Great Neck

Rochester

Chapel Hill

Fayetteville

Greensboro

Raleigh

Wilmington

Winston-Salem

Cincinnati

Dayton

Norman

Oklahoma City

Medford

Portland

Beaver Falls

Harrisburg

Lansdale

Warwick

Anderson

Charleston

Goose Creek

Mt. Pleasant

Sioux Falls

Bristol

Chattanooga

Johnson City

Nashville

Amarillo

Austin

Beaumont

Bryan

El Paso

Fort Worth

Houston

Odessa

San Antonio

Midvale

Ogden

Newport News

Norfolk

Spokane

Milwaukee

Monroe

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Takeda

INDUSTRY